Related Experiment Video

Updated: May 6, 2026

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

2.6K

Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis

Arnaud S Girard1, Audrey Paulin1, Hasanga D Manikpurage1

  • 1Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval Québec QC Canada.

Journal of the American Heart Association
|March 13, 2025
PubMed

Insights

High lipoprotein(a) levels increase the risk of cardiovascular events in patients with calcific aortic valve stenosis (CAVS). Further research into lipoprotein(a)-lowering therapies is recommended for managing CAVS outcomes.

Area of Science:

  • Cardiology
  • Biochemistry
  • Genetics

Background:

  • Lipoprotein(a) (Lp(a)) is a known independent risk factor for calcific aortic valve stenosis (CAVS).
  • The association between elevated Lp(a) levels and adverse cardiovascular or valvular outcomes in CAVS patients remains unclear.

Purpose of the Study:

  • To investigate the relationship between Lp(a) levels and the risk of valvular and cardiovascular events in patients diagnosed with CAVS.

Main Methods:

  • A cohort of 1962 UK Biobank participants with CAVS and no prior aortic valve replacement was analyzed.
  • Cox proportional hazard regression models were employed to assess the impact of Lp(a) on outcomes over a 5-year follow-up period.

Main Results:

  • Patients with Lp(a) levels ≥125 nmol/L had a significantly higher risk of aortic valve replacement (HR, 1.58), AVR or cardiac death (HR, 1.43), and overall cardiovascular/valvular events (HR, 1.36).
  • These associations remained consistent across different demographic and clinical subgroups.

Conclusions:

  • Elevated Lp(a) levels are a significant predictor of adverse valvular and cardiovascular outcomes in patients with CAVS.
  • Long-term randomized clinical trials are warranted to evaluate the efficacy of Lp(a)-lowering therapies in improving cardiovascular health for CAVS patients.
Abstract

Keywords:
aortic valve replacementcalcific aortic valve stenosisheart failurelipoprotein(a)myocardial infarctionstroke

More Related Videos

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

3.9K
Isolation of Human Primary Valve Cells for In vitro Disease Modeling07:31

Isolation of Human Primary Valve Cells for In vitro Disease Modeling

Published on: April 16, 2021

2.6K

Related Concept Videos

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
976
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
1.6K
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
1.2K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747